A meaningful share of the people buying these drugs are not buying them for a number on a scale. They are buying them because eating feels different on them, and because the thing that was hardest to control appears to become controllable. That is a serious reason, and it deserves a straight account of how much evidence sits behind it — the same account this site gives of the weight claims in is a GLP-1 worth what it costs.
How much evidence there is
A 2025 systematic review and meta-analysis found five studies of GLP-1 agonists in binge eating disorder, pooling 182 participants in total [1]. That is the whole randomized literature, and it is roughly the size of a single phase 2 arm elsewhere in this field.
Across those studies, Binge Eating Scale scores improved by 8.14 points against control (95% CI 13.13 to 3.15). Weight fell by 3.81 kg more than control (95% CI 5.14 to 2.49), BMI by 1.48 kg/m² and waist circumference by 3.14 cm. Those weight figures are modest beside the trials collected in what a GLP-1 actually costs.
What the online market has to do with it
Nothing, formally, and that is the point. No storefront tracked on this site is licensed to treat an eating disorder, none of them advertises that they do, and an intake questionnaire is not a diagnostic instrument. A person buying a compounded vial because eating feels uncontrollable is buying a weight-loss product and hoping it does something the product was not sold to do.
That may still work. What it does not come with is anyone watching. Most sellers here publish nothing about who reviews a case, how often, or how to reach them — the silence we count in what nobody says about a higher dose applies to the clinical side as much as to the price.
The practical reading
The direction of the evidence is favorable and its quantity is small. If binge eating is the reason for interest, that is a reason to involve a clinician who can diagnose it and monitor what happens, rather than a reason to avoid the drug. It is also worth knowing what stopping does, since the effect on eating is an on-treatment effect like every other one here — covered in what stopping costs and in two-thirds stop within a year.